Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 6/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LPL | P06858 | 1/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968976 | 0.87 | CCR3 (0.57) | CCR3MEN1KMT2A | |
| SCHEMBL4969395 | 0.85 | LIPG (0.57) | CCR3MAPTLPLLIPGSIGMAR1 | |
| SCHEMBL4970299 | 0.81 | CCR3 (0.52) | CCR3MEN1KMT2ASIGMAR1 | |
| SCHEMBL4965105 | 0.77 | CCR3 (0.49) | CCR3LPLLIPG | |
| SCHEMBL14110626 | 0.75 | HRH1 (0.65) | CCR3HRH1KCNH2MEN1KMT2A | |
| SCHEMBL27751691 | 0.75 | HRH1 (0.65) | CCR3HRH1KCNH2MEN1KMT2A | |
| SCHEMBL4969175 | 0.74 | MAPT (0.53) | CCR3HRH1KCNH2MAPTLPL | |
| SCHEMBL7780277 | 0.74 | MAPT (0.60) | MAPTHTTGFERSMN1; SMN2MEN1 | |
| SCHEMBL4968592 | 0.73 | HRH1 (0.80) | CCR3HRH1KCNH2 | |
| SCHEMBL11892981 | 0.73 | DRD2 (0.54) | CCR3SMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625114-B1 | Piperidine derivatives for the the treatment of chemokine or H1 mediated diseases | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |